Breaking News, Collaborations & Alliances

AZ Buys ADC Asset

Spirogen folded into MedImmune for as much as $440 million

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

AstraZeneca‘s biologics R&D arm, MedImmune, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate (ADC) technology for use in oncology. Spirogen’s proprietary pyrrolobenzodiazepine (PBD) technology attaches highly potent cytotoxic agents to specific cancer-targeting antibodies using biodegradable linkers. MedImmune will acquire 100% of Spirogen’s shares for $200 million upfront, with the potential for another $240 million based on reaching predeter...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters